Global Tardive Dyskinesia (TD) Treatment Market: Overview

Tardive dyskinesia (TD) is a neurological disorder that has the involvement of the involuntary movements. The terms can be described as tardive which means delayed and dyskinesia which means abnormal movement. The symptoms of tardive dyskinesia include finger movement, facial grimacing, jaw swinging, repetitive chewing, continuous blinking of the eyes, tongue thrusting, and others. The side effect of the neuroleptics medicines is tardive dyskinesia. These medicines are also known as major tranquilizers or antipsychotics. These medicines are mainly used for treating mental issues. Tardive dyskinesia occurs when you are on the medication for many months or years. As the drug that can be used for the treatment of tardive dyskinesia is not approved and method of treatment is also yet not confirmed thus the treatment of the disease is a difficult task. The tardive dyskinesia treatment affects the neurological system of the patient.

Global Tardive Dyskinesia (TD) Treatment Market: Segmentation

The global market for tardive dyskinesia treatment is fragmented into drug and end-user. On the basis of the drug, the global market is segregated into valbenazine, amantadine, tetrabenazine, clonazepam, and others. On the basis of the end user, the market is categorized into pharmacies, hospitals, and drug stores.

Global Tardive Dyskinesia (TD) Treatment Market: Growth Factors

The market for the tardive dyskinesia treatment will grow significantly in the coming years. The key factor that is driving the tardive dyskinesia treatment market is the increasing number of people that are suffering from the neurological disorders. In North America majority of the population is suffering from tardive dyskinesia and the people are looking forward to the treatment, thus boosting the growth of the market. The factor that is hindering the market growth is the approval process of the new treatment methods by the respective association.

Global Tardive Dyskinesia (TD) Treatment Market: Regional Analysis

The global tardive dyskinesia treatment market is regionally diversified into Eastern Europe, Latin America, the Middle East & Africa, Western Europe, North America, and Asia Pacific. The region that is dominating the tardive dyskinesia treatment market is North America. The market players in the North American region actively participate in the development of the new drugs for the treatment and the research activities and also this region has the highest demand for the neurological drugs. The regions that are following North America are Europe and Asia Pacific. The factor that these regions are also actively contributing to the research activities and are taking initiatives in building awareness about the tardive dyskinesia treatment.

Request Free Sample Report @

Global Tardive Dyskinesia (TD) Treatment Market: Competitive Players

The key market players that are involved in the tardive dyskinesia treatment market include Teva Pharmaceutical Industries Ltd., Biogen, Johnson & Johnson Services, Inc., GlaxoSmithKline Plc., Neurocrine Biosciences, Inc., Pfizer Inc., Novartis AG, Sanofi, AstraZeneca, and Bayer AG.